Modern Healthcare News
 
RSS feed

Gilead Sciences news and information

Magazine
New hepatitis C drug costs nearly $100,000
By Paul Demko | October 11, 2014 | Print Magazine Print Magazine Subscription Details
A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.
FULL STORY »
 

News
Gilead Sciences gets go-ahead for Harvoni, its second high-priced hepatitis C drug
Paul Demko | October 10, 2014 | Basic Web Basic Web Subscription Details
A second potential blockbuster drug manufactured by Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, the drug is certain to spark further debate over the pricing of specialty drugs
FULL STORY »
 

Magazine
How healthcare's Washington lobbying machine gets the job done
By Paul Demko | October 04, 2014 | Print Magazine Print Magazine Subscription Details
Providers, insurers, drug and device manufacturers, and the major trade associations are among the largest funders of the inside-the-Beltway influence industry. This year, they're on pace to spend nearly $500 million seeking to advance policies or avoid setbacks on issues crucial to their interests.
FULL STORY »
 

Vital Signs
State Medicaid directors balk at Sovaldi rebate offer
Virgil Dickson | October 02, 2014
Sovaldi-maker Gilead Sciences is making state Medicaid directors an offer they feel they must refuse, said Matt Salo, executive director of the National Association of Medicaid Directors, who spoke Wednesday at a Medicaid conference sponsored by America's Health Insurance Plans.
FULL STORY »
 

News
Operating losses persist for Temple University Health System
Bob Herman | September 26, 2014 | Basic Web Basic Web Subscription Details
Temple University Health System, a three-hospital academic medical center in northern Philadelphia, continues to lose money in its day-to-day operations, the result of lower-than-expected volumes and significant numbers of Medicare and Medicaid patients.
FULL STORY »
 


Advertisement | View Media Kit

News
8% of patients stop taking Sovaldi, CVS study finds
Jaimy Lee | September 17, 2014 | Basic Web Basic Web Subscription Details
About 8% of the patients who started taking Sovaldi to treat hepatitis C discontinued their treatment regimen prior to its conclusion, according to an analysis released Wednesday by CVS Health. The findings raise questions about how effective the costly drug will be in a larger patient population...
FULL STORY »
 

Information
Maker of hepatitis C drug strikes deal on generics for poor countries
New York Times | September 15, 2014
Gilead Sciences, the maker of one of the costliest drugs in the world, announced on Monday that it had struck agreements with seven Indian generic-drug makers to sell lower-cost versions of the medicine—a $1,000-a-pill hepatitis C treatment—in poorer countries.
FULL STORY »
 

Magazine
IT entrepreneurs rush into healthcare, but will human touch be missing?
Darius Tahir | September 06, 2014 | Print Magazine Print Magazine Subscription Details
The vision of providing better, faster, cheaper and more consumer-friendly healthcare is shared by many digital health and telehealth startups. Still, shifting healthcare services to the digital realm involves new challenges in ensuring quality and appropriate utilization.
FULL STORY »
 

News
Generic drugs, low enrollment dampened Medicare Part D spending: CBO
Bob Herman | July 30, 2014 | Basic Web Basic Web Subscription Details
The cost of Medicare Part D, the federal prescription drug program, has been far lower than originally predicted, new data from the Congressional Budget Office show. A massive slowdown in drug spending growth and low participation in the program have played the biggest roles.
FULL STORY »
 

Vital Signs
Sovaldi likely to cost Medicare billions
Virgil Dickson | July 29, 2014
The rising cost of hepatitis C drugs like Sovaldi and Olysio will increase Medicare Part D spending by $2.9 billion to $5.8 billion next year and could drive up premiums as much as 8.6%, according to a new report by the actuarial firm Milliman.
FULL STORY »
 

Search ModernHealthcare.com:


 

Switch to the new Modern Healthcare Daily News app

For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.